SLC5A2 and Cirrhosis: For treating T2DM, glucagon-like peptide-1 receptor agonists and coagonists, sodium-glucose cotransporter-2 inhibitors, metformin (if glomerular filtration rate exceeds 30 mL/min), and insulin (in decompensated cirrhosis) are preferred.